Resources from the same session
Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer
Presenter: All Speakers
Session: AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Resources:
Webcast
Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer
Presenter: All Speakers
Session: AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Resources:
Webcast
Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer
Presenter: All Speakers
Session: AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Resources:
Webcast
Shared decision-making in HR-positive, HER2-negative early breast cancer: Enhancing patient-provider communication
Presenter: All Speakers
Session: AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Resources:
Webcast
Questions and take-home messages
Presenter: All Speakers
Session: AiCME - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use?
Resources:
Webcast